Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia.
Maureen M O'BrienTodd A AlonzoTodd M CooperJohn E LevinePatrick A BrownTamra SloneKeith J AugustBouchra BenettaibNoha BisernaJennifer PoonMeera PatturajanNianhang ChenMathew SimcockLinda ZimmermanE Anders KolbPublished in: Pediatric blood & cancer (2021)
In this population of pediatric patients with R/R AML, safety data were consistent with the known safety profile of lenalidomide. As only one patient responded, further evaluation of lenalidomide at the dose and schedule studied is not warranted in pediatric AML, with the possible exception of patients with del(5q).
Keyphrases
- acute myeloid leukemia
- multiple myeloma
- newly diagnosed
- open label
- allogeneic hematopoietic stem cell transplantation
- stem cell transplantation
- chronic lymphocytic leukemia
- electronic health record
- case report
- big data
- acute lymphoblastic leukemia
- phase ii study
- high dose
- artificial intelligence
- diffuse large b cell lymphoma
- phase iii
- double blind
- machine learning
- young adults
- data analysis
- hodgkin lymphoma